Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

460 - Pre-existing antibody profiles related to immune-related adverse events in advanced non-small-cell lung cancer patients treated with anti PD-1 antibody


24 Nov 2018


Poster display - Cocktail


Immunotherapy;  Supportive Care and Symptom Management

Tumour Site


Yukihiro Toi


Annals of Oncology (2018) 29 (suppl_9): ix150-ix169. 10.1093/annonc/mdy425


Y. Toi, S. Sugawara, J. Sugisaka, H. Ono, M. Asou, K. Tsurumi, K. Suzuki, H. Shimizu, Y. Domeki, T. Aiba, S. Kawana, R. Saito, K. Terayama, Y. Kawashima, A. Nakamura, S. Yamanda, Y. Kimura, Y. Honda

Author affiliations

  • Pulmonary Medicine, Sendai Kousei Hospital, 980-0873 - Sendai/JP


Abstract 460


Immune checkpoint inhibitor (ICI) has now become the new standard treatment for non-small-cell lung cancer (NSCLC). Immune-related adverse events (irAEs) are frequently observed. Little is known about the predictor of the development of irAEs in NSCLC patients.


Patients with advanced NSCLC treated with nivolumab or pembrolizumab monotherapy at Sendai Kousei Hospital (n = 137) between January 2016 to January 2018 were included in our study. Subjects were divided into either each pre-existing antibody group or non-pre-existing antibody group, and we analyzed the association with clinical benefit and irAEs. They were also further categorized into either the irAEs-incident group (irAEs group) or non-irAEs-incident group (Non-irAEs group) and we analyzed available predictive factors of development of irAEs in clinical setting. Antibody were drawn at screening to measure immune safety parameters (anti-thyroglobulin antibody, anti-thyroid peroxidase antibody, rheumatoid factor (RF), and antinuclear antibody (ANA)).


Categorization of irAEs identified 14 of interstitial pneumonia (10%), 42 of skin reactions (31%), 16 of thyroid dysfunction (12%), and 6 of hepatitis (4%), 5 of myositis/peripheral neuropathy (4%). The following were observed: patient background (irAEs/Non-irAEs group) number of cases 66/71 cases, median age 68/67 years old, male 82/72%, treatment response CR/PR/SD/PD (1/37/27/5)/(1/8/26/36), ORR 52% (34 cases)/13% (9 cases) [Odds ratio: 0.137, p <.001]. Univariate analysis identified a significantly more pre-positivity RF in the irAEs group than in the non-irAEs group. Upon multivariate analysis, the pre-existing of RF [Odds ratio: 0.30, p = 0.003] and the pre-existing of ANA [Odds ratio: 0.47, p = 0.028] were identified as independent predictors of development of irAEs. Median PFS (months) of pre-existing RF group was significantly longer than that of non-pre-existing RF group [10.1/3.7 months, respectively, HR (95% CI) 0.61 (0.38–0.97), p = 0.036].


The pre-existing of RF for NSCLC were independent predictors of development of irAEs and might be associated with improved outcomes.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Sendai Kousei Hospital.


Has not received any funding.


S. Sugawara: Ono Pharmaceutical Co, Bristol-Myers Squibb, MSD. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.